However, we would predict that Lynch syndrome patients with hMSH6 germline mutations would have a marked reduction in survival outcome with treatment for CRC compared to patients who retain MMR function in their tumors due to loss of hMutSα. This evidence concerns the gene MSH6 and colorectal carcinoma.